Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Mike, this is very helpful.
I concur; however, anticipation had been building for this announcement. Could be MMs doing their thing.
Unfortunately market reaction has been ho-hum to down.
Pretty significant development. I expect the Form 8 to be filed soon. The discussion of potential new or enhanced formulations of Tollovid is interesting.
NPR Article: "Life expectancy in the U.S. continues to drop, driven by COVID-19"
https://www.npr.org/sections/health-shots/2022/08/31/1120192583/life-expectancy-in-the-u-s-continues-to-drop-driven-by-covid-19
Tollovid/Tollovir could be major keys to help reverse this negative trend.
Thanks JFB. Gerald is acutely aware of shareholder concerns about the increased share count and we should learn more about this issue tomorrow. I have to think that the explanation will be positive. Gerald had a window of opportunity to buy stock after the filing of the quarterly report and he purchased 1,000,000 shares at 0.032 on Aug 24. I doubt that he would have made that investment if he thought the market would react negatively to the "deal making" that we should learn about tomorrow.
Interesting conjecture...and it makes sense. I guess we'll know soon enough.
Mike, I think you are correct. I received confirmation today that I would not be called to testify for the prosecution. I had received a subpoena last month and had been awaiting further instructions on when to testify.
CNBC/Brookings article: "Long Covid is responsible for about a third of unfilled jobs in the U.S., new research suggests"
https://www.cnbc.com/2022/08/26/brookings-long-covid-keeps-millions-of-americans-out-of-workforce.html?&qsearchterm=Long%20Covid
Sooner or later leaders will recognize the contribution Tollovid could make in helping the economy by boosting workers immune system to fight Covid/Long-Covid...and keeping them in the workforce.
I'm not sure what your are concerned about. This is the Form 4 that Gerald filed the same day he bought 1,000,000 shares. If he disposed of shares he would also need to file a Form 4.
https://www.sec.gov/Archives/edgar/data/1566928/000149315222023920/xslF345X03/ownership.xml
I like the doo-rag...and he's on the beach...and he's bald.
I think this is the first real confirmation that we've seen that Jon Najarian actually owns TOMDF shares.
Great video with Jon Najarian regarding Monkeypox and Todos Medical::
https://twitter.com/i/status/1563162446696632320
Yikes! Dramatic examples.
This is important research. It certainly makes sense that patients with long covid would probably have a more difficult time coping with Monkeypox. But there are a myriad of other viruses, infections, and various maladies that one can have and also demonstrate difficulty overcoming if they are also coping with long covid. Lots of opportunity to help mankind with the products and services at Todos.
I agree with you about the recent strong press releases; however, historically PRs have not provided Todos much, if any traction. In fact the stock has traded lower many times after what seemingly was very positive news. The CEO's purchase of a million shares and submittal of the SEC Form 4 will probably do more for investor confidence than the most positive PR. I think Todos has a very bright future once it finally gets its finances in order and I know they are working hard on that issue.
This action may have an impact on investor's perception of proposals in the upcoming Proxy vote. For example, I was inclined to vote against the proposed reverse split but now may reconsider since the CEO now has his own investment in the company to consider.
This could be the catalyst we've been looking for to garner more interest in Todos. Very significant development!
This is very encouraging. GC kept his word and purchased shares. Let's see if other insiders do so as well.
The news and the 10Q presented investors with a mixed bag. There are many promising developments from existing products and services and much potential in new opportunities. Many investors were probably hoping for better revenue numbers and were at least looking for break even numbers instead of another Penney per share loss.
Thanks JFB. Tuesday's conference call should be very informative, and hopefully encouraging.
Press Release:
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
https://investor.todosmedical.com/news-events/press-releases/detail/215/todos-medical-reports-pre-print-of-publication-detailing
Thanks for the post. It appears that the trial is moving more quickly than I anticipated.
SEC Pre Schedule 14-A from Edgar... Proxy Statement regarding upcoming annual meeting:
https://www.sec.gov/Archives/edgar/data/1645260/000114036122029420/edge20004848x1_pre14a.htm
Looking forward to any news from Todos. The company has many significant initiatives in play. Of course the news could be an announcement about the 10-Q that is due Monday.
Disregard
Does anyone have any knowledge of what Mark has been doing these past couple of years...besides preparing for trial?
Covid Dashboard from Johns Hopkins: https://coronavirus.jhu.edu/map.html
Reported cases of covid are rising and it is only August...and cases are undercounted because of at- home antigen testing. This trend doesn't portend well for this fall and winter. Tollovid and Tollovir are two important keys in mitigating covid and long-covid.
Sorry...wrong board!
Million share bid at 0.026...someone is interested.
Nice start for the day...up 34%.
Good to see it over at Seekingalpha as well:
Thanks for the prompt response! This is what I was looking for:
"Todos recently received a third party valuation for 3CL Pharma of over $1.9 billion, and as a result, we believe we can raise capital at attractive valuation for both investors and Todos that will allow 3CL Pharma to maximize its potential. We expect the offerings to be in the market in late June 2022 and we are currently preparing a Tollovid manufacturing run to be used to reward 3CL Pharma investors with supply of Tollovid. By raising funding for 3CL Pharma in this way we are providing investors who believe in Tollovid, Tollovir and Tollotest with an opportunity to directly impact 3CL Pharma’s ability to widely distribute Tollovid, while also limiting Todos’ cash burn going forward."
Thanks JFB...important development to help mitigate this disfiguring virus. BTW can you refer me to the tweet/PR or other source where GC discussed the valuation he received on Tollovid/Tollovir. I've lost track of the source document. Thanks again!
New/updated Tollovid marketing video I received today in email from mytollovid.com.
TOMDF's quarterly report will be out soon. GC has indicated that he may purchase shares once the 10Q is out. It would be a real vote of confidence if we saw a flurry of Form 4s from GC and the other insiders.
There will be a reverse split...that is already planned. The extent of the split is to be determined. Timing is everything!
Covid stats:
https://coronavirus.jhu.edu/map.html